These Biopharma Names Don’t Have the Flash of SpaceX, but They’re Reliable
Here are four biotech plays that should stand up if the market starts to break down.
I’m Eyeing 2 Biopharma Stocks While Everyone Else Gawks at Big Tech
Here are a couple of oncology names that are steadily moving up.
Citigroup and I Are Aligned on These 3 Mid-Cap Biopharma Stocks
These names have attractive risk/reward profiles in an overbought market.